NCT01133899 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

BORSOOK ME, BORSOOK H
Treatment of cardiac decompensation with betaine and glycocyamine. Ann West Med Surg. 1951 Oct;5(10):830-55.
da Silva RP, Nissim I, Brosnan ME, Brosnan JT
Creatine synthesis: hepatic metabolism of guanidinoacetate and creatine in the rat in vitro and in vivo. Am J Physiol Endocrinol Metab. 2009 Feb;296(2):E256-61. doi: 10.1152/ajpendo.90547.2008. Epub 2008 Nov 18.
Edison EE, Brosnan ME, Meyer C, Brosnan JT
Creatine synthesis: production of guanidinoacetate by the rat and human kidney in vivo. Am J Physiol Renal Physiol. 2007 Dec;293(6):F1799-804. Epub 2007 Oct 10.
Mudd SH, Poole JR
Labile methyl balances for normal humans on various dietary regimens. Metabolism. 1975 Jun;24(6):721-35.
Ostojic SM
Creatine supplementation in young soccer players. Int J Sport Nutr Exerc Metab. 2004 Feb;14(1):95-103.
Setoue M, Ohuchi S, Morita T, Sugiyama K
Hyperhomocysteinemia induced by guanidinoacetic acid is effectively suppressed by choline and betaine in rats. Biosci Biotechnol Biochem. 2008 Jul;72(7):1696-703. Epub 2008 Jul 7.

The Effects of Medium-term Oral Guanidinoacetic Acid (GAA) Administration on Human Performance, Body Composition, and Metabolic Outcomes in Physically Active Men and Women

Details for clinical trial NCT01133899

Clinical trial NCT01133899 - References